nodes	percent_of_prediction	percent_of_DWPC	metapath
Diflunisal—PTGS2—melanoma	0.344	0.529	CbGaD
Diflunisal—ALB—melanoma	0.307	0.471	CbGaD
Diflunisal—ALB—Vemurafenib—melanoma	0.0695	1	CbGbCtD
Diflunisal—Niclosamide—STAT3—melanoma	0.00414	0.399	CrCbGaD
Diflunisal—Gastrointestinal perforation—Docetaxel—melanoma	0.00331	0.0321	CcSEcCtD
Diflunisal—PTGS2—leg—melanoma	0.00255	0.103	CbGeAlD
Diflunisal—PTGS2—hindlimb—melanoma	0.00228	0.0923	CbGeAlD
Diflunisal—TTR—neck—melanoma	0.00224	0.0907	CbGeAlD
Diflunisal—Photosensitivity—Vemurafenib—melanoma	0.0021	0.0204	CcSEcCtD
Diflunisal—Olsalazine—IFNG—melanoma	0.0021	0.202	CrCbGaD
Diflunisal—UGT1A8—head—melanoma	0.00206	0.0834	CbGeAlD
Diflunisal—PTGS2—appendage—melanoma	0.00195	0.0792	CbGeAlD
Diflunisal—Cholestasis—Temozolomide—melanoma	0.00171	0.0166	CcSEcCtD
Diflunisal—TTR—eye—melanoma	0.00166	0.0675	CbGeAlD
Diflunisal—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00166	0.0161	CcSEcCtD
Diflunisal—TTR—retina—melanoma	0.00165	0.0669	CbGeAlD
Diflunisal—PTGS2—skin epidermis—melanoma	0.00163	0.0659	CbGeAlD
Diflunisal—Photosensitivity reaction—Vemurafenib—melanoma	0.00145	0.0141	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00141	0.0137	CcSEcCtD
Diflunisal—Hearing impaired—Temozolomide—melanoma	0.00136	0.0132	CcSEcCtD
Diflunisal—Disorientation—Bleomycin—melanoma	0.00125	0.0121	CcSEcCtD
Diflunisal—PTGS1—endothelium—melanoma	0.00123	0.05	CbGeAlD
Diflunisal—Erythema multiforme—Vemurafenib—melanoma	0.00121	0.0117	CcSEcCtD
Diflunisal—PTGS2—endothelium—melanoma	0.00118	0.0478	CbGeAlD
Diflunisal—PTGS1—blood vessel—melanoma	0.00114	0.0461	CbGeAlD
Diflunisal—PTGS2—blood vessel—melanoma	0.00109	0.0441	CbGeAlD
Diflunisal—Deafness—Temozolomide—melanoma	0.00105	0.0102	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Temozolomide—melanoma	0.000999	0.0097	CcSEcCtD
Diflunisal—Olsalazine—PPARG—melanoma	0.000988	0.0951	CrCbGaD
Diflunisal—Gastrointestinal haemorrhage—Carmustine—melanoma	0.000975	0.00947	CcSEcCtD
Diflunisal—Bronchospasm—Bleomycin—melanoma	0.00095	0.00922	CcSEcCtD
Diflunisal—TTR—head—melanoma	0.000945	0.0383	CbGeAlD
Diflunisal—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.000938	0.00911	CcSEcCtD
Diflunisal—Hearing impaired—Docetaxel—melanoma	0.000907	0.00881	CcSEcCtD
Diflunisal—Anaphylactic shock—Vemurafenib—melanoma	0.000906	0.0088	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Temozolomide—melanoma	0.000849	0.00824	CcSEcCtD
Diflunisal—Stomatitis—Bleomycin—melanoma	0.000839	0.00815	CcSEcCtD
Diflunisal—Haematuria—Bleomycin—melanoma	0.000821	0.00797	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000796	0.00773	CcSEcCtD
Diflunisal—Decreased appetite—Vemurafenib—melanoma	0.000788	0.00765	CcSEcCtD
Diflunisal—Stomatitis—Dactinomycin—melanoma	0.000783	0.0076	CcSEcCtD
Diflunisal—Fatigue—Vemurafenib—melanoma	0.000781	0.00759	CcSEcCtD
Diflunisal—Constipation—Vemurafenib—melanoma	0.000775	0.00753	CcSEcCtD
Diflunisal—Lightheadedness—Docetaxel—melanoma	0.000772	0.0075	CcSEcCtD
Diflunisal—Dysuria—Temozolomide—melanoma	0.000762	0.0074	CcSEcCtD
Diflunisal—Agranulocytosis—Dactinomycin—melanoma	0.000749	0.00728	CcSEcCtD
Diflunisal—Photosensitivity reaction—Temozolomide—melanoma	0.000743	0.00722	CcSEcCtD
Diflunisal—Renal failure—Carmustine—melanoma	0.000739	0.00717	CcSEcCtD
Diflunisal—Stomatitis—Carmustine—melanoma	0.000733	0.00711	CcSEcCtD
Diflunisal—Mesalazine—PPARG—melanoma	0.000729	0.0701	CrCbGaD
Diflunisal—Hepatitis—Dactinomycin—melanoma	0.000721	0.007	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00072	0.00699	CcSEcCtD
Diflunisal—Flushing—Bleomycin—melanoma	0.000717	0.00697	CcSEcCtD
Diflunisal—Body temperature increased—Vemurafenib—melanoma	0.000716	0.00696	CcSEcCtD
Diflunisal—Stomatitis—Temozolomide—melanoma	0.000708	0.00687	CcSEcCtD
Diflunisal—Deafness—Docetaxel—melanoma	0.000701	0.0068	CcSEcCtD
Diflunisal—Erythema multiforme—Dactinomycin—melanoma	0.000682	0.00662	CcSEcCtD
Diflunisal—Hallucination—Carmustine—melanoma	0.000671	0.00652	CcSEcCtD
Diflunisal—Flushing—Dactinomycin—melanoma	0.000669	0.0065	CcSEcCtD
Diflunisal—Hypersensitivity—Vemurafenib—melanoma	0.000668	0.00648	CcSEcCtD
Diflunisal—Visual disturbance—Docetaxel—melanoma	0.000661	0.00642	CcSEcCtD
Diflunisal—Renal impairment—Docetaxel—melanoma	0.000659	0.0064	CcSEcCtD
Diflunisal—Hepatitis—Temozolomide—melanoma	0.000652	0.00633	CcSEcCtD
Diflunisal—Asthenia—Vemurafenib—melanoma	0.00065	0.00632	CcSEcCtD
Diflunisal—Visual impairment—Carmustine—melanoma	0.00065	0.00631	CcSEcCtD
Diflunisal—Hallucination—Temozolomide—melanoma	0.000649	0.0063	CcSEcCtD
Diflunisal—Pruritus—Vemurafenib—melanoma	0.000641	0.00623	CcSEcCtD
Diflunisal—Visual impairment—Temozolomide—melanoma	0.000628	0.0061	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000627	0.00609	CcSEcCtD
Diflunisal—Flushing—Carmustine—melanoma	0.000626	0.00608	CcSEcCtD
Diflunisal—Diarrhoea—Vemurafenib—melanoma	0.00062	0.00602	CcSEcCtD
Diflunisal—Erythema multiforme—Temozolomide—melanoma	0.000616	0.00599	CcSEcCtD
Diflunisal—Tinnitus—Temozolomide—melanoma	0.000608	0.0059	CcSEcCtD
Diflunisal—Flushing—Temozolomide—melanoma	0.000605	0.00588	CcSEcCtD
Diflunisal—Dizziness—Vemurafenib—melanoma	0.000599	0.00582	CcSEcCtD
Diflunisal—Vomiting—Vemurafenib—melanoma	0.000576	0.0056	CcSEcCtD
Diflunisal—Chest pain—Bleomycin—melanoma	0.000573	0.00556	CcSEcCtD
Diflunisal—Rash—Vemurafenib—melanoma	0.000571	0.00555	CcSEcCtD
Diflunisal—Dermatitis—Vemurafenib—melanoma	0.000571	0.00554	CcSEcCtD
Diflunisal—Headache—Vemurafenib—melanoma	0.000568	0.00551	CcSEcCtD
Diflunisal—Cramp muscle—Docetaxel—melanoma	0.000564	0.00548	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000564	0.00548	CcSEcCtD
Diflunisal—Confusional state—Bleomycin—melanoma	0.000554	0.00538	CcSEcCtD
Diflunisal—Vision blurred—Carmustine—melanoma	0.000553	0.00538	CcSEcCtD
Diflunisal—Anaphylactic shock—Bleomycin—melanoma	0.000549	0.00533	CcSEcCtD
Diflunisal—Oedema—Bleomycin—melanoma	0.000549	0.00533	CcSEcCtD
Diflunisal—Nausea—Vemurafenib—melanoma	0.000538	0.00523	CcSEcCtD
Diflunisal—Thrombocytopenia—Bleomycin—melanoma	0.000538	0.00522	CcSEcCtD
Diflunisal—Vision blurred—Temozolomide—melanoma	0.000535	0.00519	CcSEcCtD
Diflunisal—Bronchospasm—Docetaxel—melanoma	0.000533	0.00517	CcSEcCtD
Diflunisal—PTGS1—skin of body—melanoma	0.000527	0.0213	CbGeAlD
Diflunisal—Anorexia—Bleomycin—melanoma	0.000523	0.00508	CcSEcCtD
Diflunisal—Angioedema—Temozolomide—melanoma	0.000519	0.00504	CcSEcCtD
Diflunisal—Oedema—Dactinomycin—melanoma	0.000512	0.00497	CcSEcCtD
Diflunisal—Vertigo—Temozolomide—melanoma	0.00051	0.00495	CcSEcCtD
Diflunisal—PTGS2—skin of body—melanoma	0.000504	0.0204	CbGeAlD
Diflunisal—Palpitations—Temozolomide—melanoma	0.000502	0.00487	CcSEcCtD
Diflunisal—Thrombocytopenia—Dactinomycin—melanoma	0.000501	0.00487	CcSEcCtD
Diflunisal—Chest pain—Carmustine—melanoma	0.0005	0.00486	CcSEcCtD
Diflunisal—Paraesthesia—Bleomycin—melanoma	0.000493	0.00479	CcSEcCtD
Diflunisal—Dyspnoea—Bleomycin—melanoma	0.00049	0.00475	CcSEcCtD
Diflunisal—Anorexia—Dactinomycin—melanoma	0.000488	0.00474	CcSEcCtD
Diflunisal—Confusional state—Carmustine—melanoma	0.000483	0.00469	CcSEcCtD
Diflunisal—PTGS1—mammalian vulva—melanoma	0.00048	0.0195	CbGeAlD
Diflunisal—Oedema—Carmustine—melanoma	0.000479	0.00465	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000479	0.00465	CcSEcCtD
Diflunisal—Decreased appetite—Bleomycin—melanoma	0.000477	0.00464	CcSEcCtD
Diflunisal—Renal failure—Docetaxel—melanoma	0.000475	0.00461	CcSEcCtD
Diflunisal—Jaundice—Docetaxel—melanoma	0.000471	0.00457	CcSEcCtD
Diflunisal—Stomatitis—Docetaxel—melanoma	0.000471	0.00457	CcSEcCtD
Diflunisal—Thrombocytopenia—Carmustine—melanoma	0.000469	0.00456	CcSEcCtD
Diflunisal—Confusional state—Temozolomide—melanoma	0.000467	0.00454	CcSEcCtD
Diflunisal—Oedema—Temozolomide—melanoma	0.000463	0.0045	CcSEcCtD
Diflunisal—Anaphylactic shock—Temozolomide—melanoma	0.000463	0.0045	CcSEcCtD
Diflunisal—Anorexia—Carmustine—melanoma	0.000457	0.00444	CcSEcCtD
Diflunisal—Thrombocytopenia—Temozolomide—melanoma	0.000454	0.0044	CcSEcCtD
Diflunisal—Feeling abnormal—Bleomycin—melanoma	0.000452	0.00439	CcSEcCtD
Diflunisal—Agranulocytosis—Docetaxel—melanoma	0.000451	0.00438	CcSEcCtD
Diflunisal—Hyperhidrosis—Temozolomide—melanoma	0.000448	0.00435	CcSEcCtD
Diflunisal—Decreased appetite—Dactinomycin—melanoma	0.000445	0.00432	CcSEcCtD
Diflunisal—Fatigue—Dactinomycin—melanoma	0.000442	0.00429	CcSEcCtD
Diflunisal—Anorexia—Temozolomide—melanoma	0.000442	0.00429	CcSEcCtD
Diflunisal—Urticaria—Bleomycin—melanoma	0.000436	0.00424	CcSEcCtD
Diflunisal—Body temperature increased—Bleomycin—melanoma	0.000434	0.00422	CcSEcCtD
Diflunisal—Hepatitis—Docetaxel—melanoma	0.000434	0.00421	CcSEcCtD
Diflunisal—Insomnia—Carmustine—melanoma	0.000434	0.00421	CcSEcCtD
Diflunisal—Paraesthesia—Carmustine—melanoma	0.00043	0.00418	CcSEcCtD
Diflunisal—Dyspnoea—Carmustine—melanoma	0.000427	0.00415	CcSEcCtD
Diflunisal—Somnolence—Carmustine—melanoma	0.000426	0.00414	CcSEcCtD
Diflunisal—ALB—lymph node—melanoma	0.000422	0.0171	CbGeAlD
Diflunisal—Feeling abnormal—Dactinomycin—melanoma	0.000422	0.0041	CcSEcCtD
Diflunisal—Insomnia—Temozolomide—melanoma	0.000419	0.00407	CcSEcCtD
Diflunisal—Gastrointestinal pain—Dactinomycin—melanoma	0.000419	0.00407	CcSEcCtD
Diflunisal—Visual impairment—Docetaxel—melanoma	0.000418	0.00406	CcSEcCtD
Diflunisal—Olsalazine—PTGS2—melanoma	0.000417	0.0401	CrCbGaD
Diflunisal—Decreased appetite—Carmustine—melanoma	0.000417	0.00405	CcSEcCtD
Diflunisal—Paraesthesia—Temozolomide—melanoma	0.000416	0.00404	CcSEcCtD
Diflunisal—Dyspnoea—Temozolomide—melanoma	0.000413	0.00401	CcSEcCtD
Diflunisal—Somnolence—Temozolomide—melanoma	0.000412	0.004	CcSEcCtD
Diflunisal—Erythema multiforme—Docetaxel—melanoma	0.00041	0.00398	CcSEcCtD
Diflunisal—Constipation—Carmustine—melanoma	0.00041	0.00398	CcSEcCtD
Diflunisal—Dyspepsia—Temozolomide—melanoma	0.000408	0.00396	CcSEcCtD
Diflunisal—Body temperature increased—Dactinomycin—melanoma	0.000405	0.00393	CcSEcCtD
Diflunisal—Hypersensitivity—Bleomycin—melanoma	0.000405	0.00393	CcSEcCtD
Diflunisal—Decreased appetite—Temozolomide—melanoma	0.000403	0.00391	CcSEcCtD
Diflunisal—Flushing—Docetaxel—melanoma	0.000402	0.00391	CcSEcCtD
Diflunisal—Fatigue—Temozolomide—melanoma	0.000399	0.00388	CcSEcCtD
Diflunisal—Constipation—Temozolomide—melanoma	0.000396	0.00385	CcSEcCtD
Diflunisal—Feeling abnormal—Carmustine—melanoma	0.000395	0.00384	CcSEcCtD
Diflunisal—Asthenia—Bleomycin—melanoma	0.000394	0.00383	CcSEcCtD
Diflunisal—Aminosalicylic Acid—PTGS2—melanoma	0.000392	0.0377	CrCbGaD
Diflunisal—Gastrointestinal pain—Carmustine—melanoma	0.000392	0.00381	CcSEcCtD
Diflunisal—Pruritus—Bleomycin—melanoma	0.000388	0.00377	CcSEcCtD
Diflunisal—Feeling abnormal—Temozolomide—melanoma	0.000382	0.00371	CcSEcCtD
Diflunisal—Body temperature increased—Carmustine—melanoma	0.000379	0.00368	CcSEcCtD
Diflunisal—Gastrointestinal pain—Temozolomide—melanoma	0.000379	0.00368	CcSEcCtD
Diflunisal—Hypersensitivity—Dactinomycin—melanoma	0.000377	0.00366	CcSEcCtD
Diflunisal—Urticaria—Temozolomide—melanoma	0.000368	0.00357	CcSEcCtD
Diflunisal—Asthenia—Dactinomycin—melanoma	0.000367	0.00357	CcSEcCtD
Diflunisal—Body temperature increased—Temozolomide—melanoma	0.000366	0.00356	CcSEcCtD
Diflunisal—Muscle spasms—Docetaxel—melanoma	0.000363	0.00352	CcSEcCtD
Diflunisal—Salsalate—PTGS2—melanoma	0.000355	0.0341	CrCbGaD
Diflunisal—Hypersensitivity—Carmustine—melanoma	0.000353	0.00343	CcSEcCtD
Diflunisal—Diarrhoea—Dactinomycin—melanoma	0.00035	0.0034	CcSEcCtD
Diflunisal—Vomiting—Bleomycin—melanoma	0.000349	0.00339	CcSEcCtD
Diflunisal—Rash—Bleomycin—melanoma	0.000346	0.00336	CcSEcCtD
Diflunisal—Dermatitis—Bleomycin—melanoma	0.000346	0.00336	CcSEcCtD
Diflunisal—Asthenia—Carmustine—melanoma	0.000344	0.00334	CcSEcCtD
Diflunisal—PTGS1—head—melanoma	0.000344	0.0139	CbGeAlD
Diflunisal—Hypersensitivity—Temozolomide—melanoma	0.000341	0.00331	CcSEcCtD
Diflunisal—Syncope—Docetaxel—melanoma	0.000338	0.00329	CcSEcCtD
Diflunisal—Palpitations—Docetaxel—melanoma	0.000334	0.00324	CcSEcCtD
Diflunisal—Asthenia—Temozolomide—melanoma	0.000332	0.00323	CcSEcCtD
Diflunisal—Loss of consciousness—Docetaxel—melanoma	0.000332	0.00322	CcSEcCtD
Diflunisal—PTGS2—head—melanoma	0.000329	0.0133	CbGeAlD
Diflunisal—Diarrhoea—Carmustine—melanoma	0.000328	0.00318	CcSEcCtD
Diflunisal—Pruritus—Temozolomide—melanoma	0.000328	0.00318	CcSEcCtD
Diflunisal—Nausea—Bleomycin—melanoma	0.000326	0.00317	CcSEcCtD
Diflunisal—Vomiting—Dactinomycin—melanoma	0.000326	0.00316	CcSEcCtD
Diflunisal—Rash—Dactinomycin—melanoma	0.000323	0.00314	CcSEcCtD
Diflunisal—Chest pain—Docetaxel—melanoma	0.000321	0.00312	CcSEcCtD
Diflunisal—Dizziness—Carmustine—melanoma	0.000317	0.00308	CcSEcCtD
Diflunisal—Diarrhoea—Temozolomide—melanoma	0.000317	0.00308	CcSEcCtD
Diflunisal—Confusional state—Docetaxel—melanoma	0.000311	0.00302	CcSEcCtD
Diflunisal—Anaphylactic shock—Docetaxel—melanoma	0.000308	0.00299	CcSEcCtD
Diflunisal—Oedema—Docetaxel—melanoma	0.000308	0.00299	CcSEcCtD
Diflunisal—Mesalazine—PTGS2—melanoma	0.000308	0.0296	CrCbGaD
Diflunisal—Dizziness—Temozolomide—melanoma	0.000306	0.00297	CcSEcCtD
Diflunisal—Vomiting—Carmustine—melanoma	0.000305	0.00296	CcSEcCtD
Diflunisal—Nausea—Dactinomycin—melanoma	0.000304	0.00295	CcSEcCtD
Diflunisal—Shock—Docetaxel—melanoma	0.000303	0.00294	CcSEcCtD
Diflunisal—Rash—Carmustine—melanoma	0.000302	0.00293	CcSEcCtD
Diflunisal—Dermatitis—Carmustine—melanoma	0.000302	0.00293	CcSEcCtD
Diflunisal—Thrombocytopenia—Docetaxel—melanoma	0.000302	0.00293	CcSEcCtD
Diflunisal—Headache—Carmustine—melanoma	0.0003	0.00292	CcSEcCtD
Diflunisal—Vomiting—Temozolomide—melanoma	0.000295	0.00286	CcSEcCtD
Diflunisal—Anorexia—Docetaxel—melanoma	0.000294	0.00285	CcSEcCtD
Diflunisal—Rash—Temozolomide—melanoma	0.000292	0.00284	CcSEcCtD
Diflunisal—Dermatitis—Temozolomide—melanoma	0.000292	0.00283	CcSEcCtD
Diflunisal—Headache—Temozolomide—melanoma	0.00029	0.00282	CcSEcCtD
Diflunisal—Nausea—Carmustine—melanoma	0.000285	0.00276	CcSEcCtD
Diflunisal—Insomnia—Docetaxel—melanoma	0.000279	0.00271	CcSEcCtD
Diflunisal—Paraesthesia—Docetaxel—melanoma	0.000277	0.00269	CcSEcCtD
Diflunisal—Nausea—Temozolomide—melanoma	0.000275	0.00267	CcSEcCtD
Diflunisal—Dyspnoea—Docetaxel—melanoma	0.000275	0.00267	CcSEcCtD
Diflunisal—Somnolence—Docetaxel—melanoma	0.000274	0.00266	CcSEcCtD
Diflunisal—Dyspepsia—Docetaxel—melanoma	0.000271	0.00263	CcSEcCtD
Diflunisal—Decreased appetite—Docetaxel—melanoma	0.000268	0.0026	CcSEcCtD
Diflunisal—Fatigue—Docetaxel—melanoma	0.000266	0.00258	CcSEcCtD
Diflunisal—Constipation—Docetaxel—melanoma	0.000263	0.00256	CcSEcCtD
Diflunisal—Feeling abnormal—Docetaxel—melanoma	0.000254	0.00247	CcSEcCtD
Diflunisal—Gastrointestinal pain—Docetaxel—melanoma	0.000252	0.00245	CcSEcCtD
Diflunisal—Body temperature increased—Docetaxel—melanoma	0.000244	0.00236	CcSEcCtD
Diflunisal—PTGS1—lymph node—melanoma	0.000241	0.00975	CbGeAlD
Diflunisal—PTGS2—lymph node—melanoma	0.00023	0.00932	CbGeAlD
Diflunisal—Hypersensitivity—Docetaxel—melanoma	0.000227	0.0022	CcSEcCtD
Diflunisal—Asthenia—Docetaxel—melanoma	0.000221	0.00215	CcSEcCtD
Diflunisal—Salicylic acid—PTGS2—melanoma	0.000218	0.021	CrCbGaD
Diflunisal—Pruritus—Docetaxel—melanoma	0.000218	0.00212	CcSEcCtD
Diflunisal—Diarrhoea—Docetaxel—melanoma	0.000211	0.00205	CcSEcCtD
Diflunisal—Dizziness—Docetaxel—melanoma	0.000204	0.00198	CcSEcCtD
Diflunisal—Vomiting—Docetaxel—melanoma	0.000196	0.0019	CcSEcCtD
Diflunisal—Salicylic acid—ALB—melanoma	0.000194	0.0187	CrCbGaD
Diflunisal—Rash—Docetaxel—melanoma	0.000194	0.00189	CcSEcCtD
Diflunisal—Dermatitis—Docetaxel—melanoma	0.000194	0.00188	CcSEcCtD
Diflunisal—Headache—Docetaxel—melanoma	0.000193	0.00187	CcSEcCtD
Diflunisal—Flurbiprofen—PTGS2—melanoma	0.000191	0.0184	CrCbGaD
Diflunisal—Salicylic acid—ABCB1—melanoma	0.000185	0.0178	CrCbGaD
Diflunisal—Nausea—Docetaxel—melanoma	0.000183	0.00178	CcSEcCtD
Diflunisal—Flurbiprofen—ALB—melanoma	0.00017	0.0164	CrCbGaD
Diflunisal—ALB—Hemostasis—IFNA2—melanoma	3.58e-05	0.000253	CbGpPWpGaD
Diflunisal—TTR—Disease—ERBB2—melanoma	3.57e-05	0.000253	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—SLC5A5—melanoma	3.56e-05	0.000252	CbGpPWpGaD
Diflunisal—ALB—Metabolism—MTAP—melanoma	3.54e-05	0.000251	CbGpPWpGaD
Diflunisal—TTR—Disease—PIK3CB—melanoma	3.52e-05	0.000249	CbGpPWpGaD
Diflunisal—TTR—Disease—CD4—melanoma	3.52e-05	0.000249	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—GPAM—melanoma	3.52e-05	0.000249	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—KDR—melanoma	3.5e-05	0.000247	CbGpPWpGaD
Diflunisal—TTR—Disease—PTGS2—melanoma	3.49e-05	0.000247	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HDAC6—melanoma	3.46e-05	0.000245	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	3.46e-05	0.000245	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	3.44e-05	0.000244	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—VCAN—melanoma	3.38e-05	0.000239	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—FN1—melanoma	3.37e-05	0.000238	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—PIK3CB—melanoma	3.36e-05	0.000237	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—melanoma	3.35e-05	0.000237	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—ITGB1—melanoma	3.33e-05	0.000235	CbGpPWpGaD
Diflunisal—TTR—Disease—CDKN1B—melanoma	3.31e-05	0.000234	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NOTCH1—melanoma	3.29e-05	0.000233	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NPPA—melanoma	3.28e-05	0.000232	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	3.28e-05	0.000232	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	3.28e-05	0.000232	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—ALB—melanoma	3.26e-05	0.000231	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CD80—melanoma	3.23e-05	0.000228	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—KIT—melanoma	3.22e-05	0.000228	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—APC—melanoma	3.22e-05	0.000228	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PIK3CG—melanoma	3.22e-05	0.000228	CbGpPWpGaD
Diflunisal—PTGS2—Disease—VCAN—melanoma	3.21e-05	0.000227	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	3.2e-05	0.000226	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—EGF—melanoma	3.18e-05	0.000225	CbGpPWpGaD
Diflunisal—PTGS2—Disease—WNT5A—melanoma	3.18e-05	0.000225	CbGpPWpGaD
Diflunisal—ALB—Metabolism—LUM—melanoma	3.16e-05	0.000223	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PHGDH—melanoma	3.16e-05	0.000223	CbGpPWpGaD
Diflunisal—TTR—Disease—CTNNB1—melanoma	3.12e-05	0.000221	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—melanoma	3.12e-05	0.000221	CbGpPWpGaD
Diflunisal—ALB—Metabolism—HPSE—melanoma	3.1e-05	0.000219	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	3.09e-05	0.000219	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PPARG—melanoma	3.09e-05	0.000219	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—IL2—melanoma	3.08e-05	0.000218	CbGpPWpGaD
Diflunisal—TTR—Disease—CDKN1A—melanoma	3.05e-05	0.000216	CbGpPWpGaD
Diflunisal—TTR—Disease—PTEN—melanoma	3.05e-05	0.000215	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—HGF—melanoma	3.04e-05	0.000215	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CUBN—melanoma	3.04e-05	0.000215	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—BRAF—melanoma	3.03e-05	0.000214	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—CSF2—melanoma	3.01e-05	0.000213	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PLA2G6—melanoma	2.99e-05	0.000211	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—IGF1—melanoma	2.95e-05	0.000209	CbGpPWpGaD
Diflunisal—ALB—Metabolism—SDHD—melanoma	2.94e-05	0.000208	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CSPG4—melanoma	2.94e-05	0.000208	CbGpPWpGaD
Diflunisal—ALB—Metabolism—BSG—melanoma	2.94e-05	0.000208	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—ITGB3—melanoma	2.88e-05	0.000204	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PRKCA—melanoma	2.88e-05	0.000204	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CYP17A1—melanoma	2.85e-05	0.000202	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MAP2K1—melanoma	2.85e-05	0.000202	CbGpPWpGaD
Diflunisal—ALB—Metabolism—GPAM—melanoma	2.84e-05	0.000201	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	2.84e-05	0.000201	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PIK3CD—melanoma	2.83e-05	0.0002	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.81e-05	0.000199	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—ALB—melanoma	2.78e-05	0.000196	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—melanoma	2.75e-05	0.000195	CbGpPWpGaD
Diflunisal—TTR—Disease—STAT3—melanoma	2.72e-05	0.000193	CbGpPWpGaD
Diflunisal—TTR—Disease—NRAS—melanoma	2.72e-05	0.000192	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—ABCB1—melanoma	2.71e-05	0.000192	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—FGF2—melanoma	2.71e-05	0.000192	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—GNA11—melanoma	2.69e-05	0.000191	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—VCAN—melanoma	2.68e-05	0.00019	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—RAC1—melanoma	2.67e-05	0.000189	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—FASN—melanoma	2.64e-05	0.000187	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—VEGFA—melanoma	2.62e-05	0.000185	CbGpPWpGaD
Diflunisal—TTR—Disease—MAPK3—melanoma	2.6e-05	0.000184	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—SLC5A5—melanoma	2.59e-05	0.000183	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—MMP1—melanoma	2.59e-05	0.000183	CbGpPWpGaD
Diflunisal—PTGS2—Disease—GAB2—melanoma	2.55e-05	0.000181	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.54e-05	0.00018	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—CDK2—melanoma	2.54e-05	0.00018	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MDM2—melanoma	2.54e-05	0.000179	CbGpPWpGaD
Diflunisal—TTR—Disease—MYC—melanoma	2.53e-05	0.000179	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PIK3CA—melanoma	2.53e-05	0.000179	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—GNAQ—melanoma	2.51e-05	0.000177	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CD44—melanoma	2.51e-05	0.000177	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—ERBB2—melanoma	2.5e-05	0.000177	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FASN—melanoma	2.5e-05	0.000177	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—MAPK3—melanoma	2.48e-05	0.000175	CbGpPWpGaD
Diflunisal—TTR—Disease—MAPK1—melanoma	2.48e-05	0.000175	CbGpPWpGaD
Diflunisal—TTR—Disease—EGFR—melanoma	2.48e-05	0.000175	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PIK3CB—melanoma	2.47e-05	0.000175	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	2.45e-05	0.000173	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PPARG—melanoma	2.45e-05	0.000173	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—melanoma	2.43e-05	0.000172	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PLA2G6—melanoma	2.42e-05	0.000171	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CYP1B1—melanoma	2.4e-05	0.00017	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HDAC2—melanoma	2.4e-05	0.00017	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CXCR4—melanoma	2.4e-05	0.00017	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FOXO4—melanoma	2.4e-05	0.00017	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CD44—melanoma	2.37e-05	0.000168	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CXCL8—melanoma	2.37e-05	0.000168	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—FN1—melanoma	2.36e-05	0.000167	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—MAPK1—melanoma	2.36e-05	0.000167	CbGpPWpGaD
Diflunisal—TTR—Disease—KRAS—melanoma	2.34e-05	0.000165	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—NOS2—melanoma	2.33e-05	0.000165	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	2.32e-05	0.000164	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CDKN1B—melanoma	2.32e-05	0.000164	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CASP3—melanoma	2.27e-05	0.000161	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—IL2—melanoma	2.27e-05	0.00016	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CYP17A1—melanoma	2.27e-05	0.00016	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PIK3CG—melanoma	2.26e-05	0.00016	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	2.23e-05	0.000158	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—EGF—melanoma	2.23e-05	0.000158	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CCND1—melanoma	2.21e-05	0.000156	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—ALB—melanoma	2.21e-05	0.000156	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKT3—melanoma	2.19e-05	0.000155	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CTNNB1—melanoma	2.19e-05	0.000155	CbGpPWpGaD
Diflunisal—ALB—Metabolism—VCAN—melanoma	2.17e-05	0.000154	CbGpPWpGaD
Diflunisal—TTR—Disease—PIK3CA—melanoma	2.15e-05	0.000152	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MMP9—melanoma	2.15e-05	0.000152	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—GNA11—melanoma	2.14e-05	0.000151	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CDKN1A—melanoma	2.14e-05	0.000151	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PTEN—melanoma	2.13e-05	0.000151	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NFKB1—melanoma	2.12e-05	0.00015	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PTEN—melanoma	2.12e-05	0.00015	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—FASN—melanoma	2.09e-05	0.000148	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—IGF1—melanoma	2.07e-05	0.000146	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—AKT1—melanoma	2.06e-05	0.000146	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—SLC5A5—melanoma	2.06e-05	0.000146	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	2.06e-05	0.000145	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—PIK3CA—melanoma	2.05e-05	0.000145	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—GNAQ—melanoma	1.99e-05	0.000141	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CD44—melanoma	1.99e-05	0.000141	CbGpPWpGaD
Diflunisal—TTR—Disease—HRAS—melanoma	1.99e-05	0.000141	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PIK3CD—melanoma	1.99e-05	0.00014	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.98e-05	0.00014	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—ABCB1—melanoma	1.98e-05	0.00014	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.95e-05	0.000138	CbGpPWpGaD
Diflunisal—PTGS2—Disease—ERBB4—melanoma	1.94e-05	0.000137	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—VEGFA—melanoma	1.93e-05	0.000136	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDKN2B—melanoma	1.92e-05	0.000136	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—STAT3—melanoma	1.91e-05	0.000135	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CYP1B1—melanoma	1.91e-05	0.000135	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NRAS—melanoma	1.9e-05	0.000135	CbGpPWpGaD
Diflunisal—TTR—Disease—IL6—melanoma	1.9e-05	0.000135	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CD86—melanoma	1.86e-05	0.000131	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CYP17A1—melanoma	1.83e-05	0.00013	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MAPK3—melanoma	1.82e-05	0.000129	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PRKCA—melanoma	1.82e-05	0.000129	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.81e-05	0.000128	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—ERCC2—melanoma	1.81e-05	0.000128	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FGF1—melanoma	1.8e-05	0.000127	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MYC—melanoma	1.77e-05	0.000125	CbGpPWpGaD
Diflunisal—TTR—Disease—AKT1—melanoma	1.76e-05	0.000124	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PDGFRA—melanoma	1.74e-05	0.000123	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MAPK1—melanoma	1.73e-05	0.000123	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—EGFR—melanoma	1.73e-05	0.000123	CbGpPWpGaD
Diflunisal—ALB—Metabolism—GNA11—melanoma	1.73e-05	0.000122	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PIK3CB—melanoma	1.73e-05	0.000122	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PRKCA—melanoma	1.73e-05	0.000122	CbGpPWpGaD
Diflunisal—PTGS2—Disease—ERCC2—melanoma	1.71e-05	0.000121	CbGpPWpGaD
Diflunisal—ALB—Metabolism—FASN—melanoma	1.69e-05	0.00012	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MAP2K2—melanoma	1.69e-05	0.000119	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.68e-05	0.000119	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—AKT1—melanoma	1.67e-05	0.000118	CbGpPWpGaD
Diflunisal—ALB—Metabolism—SLC5A5—melanoma	1.67e-05	0.000118	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—KRAS—melanoma	1.64e-05	0.000116	CbGpPWpGaD
Diflunisal—ALB—Metabolism—GNAQ—melanoma	1.61e-05	0.000114	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CD44—melanoma	1.61e-05	0.000114	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HLA-A—melanoma	1.6e-05	0.000113	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TERT—melanoma	1.6e-05	0.000113	CbGpPWpGaD
Diflunisal—PTGS2—Disease—RAC1—melanoma	1.6e-05	0.000113	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—IL2—melanoma	1.59e-05	0.000112	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.58e-05	0.000111	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—ABCB1—melanoma	1.57e-05	0.000111	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.56e-05	0.00011	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CYP1B1—melanoma	1.54e-05	0.000109	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HIF1A—melanoma	1.53e-05	0.000108	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PIK3CA—melanoma	1.5e-05	0.000106	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.5e-05	0.000106	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TP53—melanoma	1.46e-05	0.000103	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PRKCA—melanoma	1.44e-05	0.000102	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—ERCC2—melanoma	1.43e-05	0.000101	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PIK3CG—melanoma	1.43e-05	0.000101	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NOS2—melanoma	1.4e-05	9.87e-05	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—HRAS—melanoma	1.39e-05	9.85e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NOTCH1—melanoma	1.38e-05	9.77e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PPARG—melanoma	1.38e-05	9.73e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.36e-05	9.63e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CD80—melanoma	1.35e-05	9.58e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—APC—melanoma	1.35e-05	9.56e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—KIT—melanoma	1.35e-05	9.56e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—VEGFA—melanoma	1.35e-05	9.55e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—EGF—melanoma	1.34e-05	9.45e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—NRAS—melanoma	1.33e-05	9.44e-05	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—IL6—melanoma	1.33e-05	9.42e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—MAPK3—melanoma	1.28e-05	9.04e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—BRAF—melanoma	1.27e-05	8.98e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—ABCB1—melanoma	1.27e-05	8.98e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PIK3CD—melanoma	1.25e-05	8.86e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—ALB—melanoma	1.24e-05	8.75e-05	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKT1—melanoma	1.23e-05	8.69e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—MAPK1—melanoma	1.22e-05	8.6e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MAP2K1—melanoma	1.2e-05	8.46e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PIK3CD—melanoma	1.19e-05	8.4e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.19e-05	8.4e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PRKCA—melanoma	1.17e-05	8.27e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—ERCC2—melanoma	1.16e-05	8.2e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—KRAS—melanoma	1.15e-05	8.12e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—FGF2—melanoma	1.14e-05	8.05e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PIK3CG—melanoma	1.13e-05	8.01e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PIK3CB—melanoma	1.09e-05	7.73e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PPARG—melanoma	1.09e-05	7.73e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PTGS2—melanoma	1.08e-05	7.66e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MDM2—melanoma	1.06e-05	7.53e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PIK3CA—melanoma	1.05e-05	7.46e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—ERBB2—melanoma	1.05e-05	7.42e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PIK3CB—melanoma	1.04e-05	7.32e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CD4—melanoma	1.03e-05	7.31e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—TP53—melanoma	1.02e-05	7.22e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PIK3CD—melanoma	9.95e-06	7.04e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—ALB—melanoma	9.82e-06	6.95e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—HRAS—melanoma	9.76e-06	6.9e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDKN1B—melanoma	9.72e-06	6.87e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	9.6e-06	6.79e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PTEN—melanoma	9.44e-06	6.68e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CTNNB1—melanoma	9.18e-06	6.49e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PIK3CG—melanoma	9.16e-06	6.48e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDKN1A—melanoma	8.97e-06	6.34e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PTEN—melanoma	8.95e-06	6.33e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PPARG—melanoma	8.84e-06	6.25e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PIK3CB—melanoma	8.67e-06	6.13e-05	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—AKT1—melanoma	8.62e-06	6.1e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PIK3CD—melanoma	8.05e-06	5.69e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—STAT3—melanoma	8e-06	5.66e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NRAS—melanoma	7.98e-06	5.65e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MAPK3—melanoma	7.65e-06	5.41e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PTEN—melanoma	7.49e-06	5.3e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MYC—melanoma	7.44e-06	5.26e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MAPK1—melanoma	7.28e-06	5.15e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—EGFR—melanoma	7.27e-06	5.14e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PIK3CB—melanoma	7.02e-06	4.96e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PTGS2—melanoma	6.95e-06	4.92e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—KRAS—melanoma	6.87e-06	4.86e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PIK3CA—melanoma	6.66e-06	4.71e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PIK3CA—melanoma	6.31e-06	4.46e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PTEN—melanoma	6.06e-06	4.29e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HRAS—melanoma	5.84e-06	4.13e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—IL6—melanoma	5.59e-06	3.95e-05	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKT1—melanoma	5.44e-06	3.85e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PIK3CA—melanoma	5.29e-06	3.74e-05	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKT1—melanoma	5.16e-06	3.65e-05	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKT1—melanoma	4.32e-06	3.05e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PIK3CA—melanoma	4.28e-06	3.03e-05	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKT1—melanoma	3.49e-06	2.47e-05	CbGpPWpGaD
